The anti-tumor effects of liver cancer-targeting long-circulating paclitaxel-containing Galactosylated liposomes

TANG Yong,LI Jian,ZHANG Yang-de

DOI: https://doi.org/10.3969/j.issn.1005-8982.2012.09.002

2012-01-01

Abstract:【Objective】 To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting liver tumor in order to improve the tissue distribution of paclitaxel in vivo,and to promote the safety and the anti-tumor efficacy of paclitaxel administration.【Methods】 A novel galactosylated lipid,(5-Cholesten-3β-y1) 4-oxo-4-[2-(1actobionyl amido) ethylamido] butanoate(CHS-ED-LA),was incorporated in the liposomes for liver targeting.Paclitaxel was uptaken into conventional liposomes(CL) and galactosylated liposomes(GalLs) by transmembrane ammonium sulfate gradient method.The pharmacokinetics,tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol,conventional liposomes(CL) or galactosylated liposomes(GalLs) in tumor-bearing nude mice.The maximum tolerance doses(MTDs) of two different formulations of paclitaxel were determined in Kunming mice.【Results】 Transmission electron microscopy(TEM) image showed that both conventional liposomes(CL) and galactosylated liposomes(GalLs) shaped regularly round and dispersed uniformly,and these two particle sizes were(78.5±27.8) nm and(88.6±32.5) nm,respectively.The encapsulation efficiencies of both conventional liposomes(CL) and galactosylated liposomes(GalLs) were at or above 25%.In vivo,the circulation time of conventional liposomes(CL) and galactosylated liposomes(GalLs) was longer than taxol,and the pharmacokinetic parameters of conventional liposomes(CL) and galactosylated liposomes(GalLs) were similar.Tumor-targeting efficiency of galactosylated liposomes(GalLs) was better than that of S conventional liposomes(CL) or taxol,as well as the tissue distribution of galactosylated liposomes(GalLs) in normal organs was at a relatively low level as compared with that of conventional liposomes(CL) or taxol,in contribution to RGD specifically targeting tumors.The MTDs of conventional liposomes(CL) and galactosylated liposomes(GalLs) were higher than that of taxol.Compared with conventional liposomes(CL) and taxol with the same dose of paclitaxel,the anti-tumor efficacy of galactosylated liposomes(GalLs) was improved significantly(P <0.05);and the mice received galactosylated liposomes(GalLs) therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.【Conclusion】 The liver cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo.